Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X for Obstructive Sleep Apnea

Incannex Healthcare Inc.

Awarded 'Best New Technology Solution for Drug Development' in 10th annual MedTech Breakthrough Awards program.
IHL-42X is a fixed-dose combination of dronabinol and acetazolamide targeting key drivers of OSA.
Phase 2 RePOSA trial showed statistically significant reductions in AHI and improvements in oxygenation, sleep quality, and fatigue.
CEO Joel Latham noted the award validates progress and potential to redefine OSA treatment paradigm.
Recognition comes as Incannex advances IHL-42X toward late-stage development and explores strategic opportunities.

item 7.01item 9.01

Source: SEC EDGAR

accession 0001213900-26-054725

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.